In8Bio, Inc. (NASDAQ: INAB)

IN8BIO, INC. (INAB), a clinical-stage biopharmaceutical company, operates in the biotechnology industry. Its primary business activities are focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. The company's operations span across various countries, with a particular focus on the United States.

IN8BIO generates revenue through the development and commercialization of its product candidates. These include INB-400, an autologous DeltEx DRI product candidate for newly diagnosed glioblastoma (GBM); INB-200, another autologous DeltEx DRI product candidate for GBM; and INB-100, an allogeneic DeltEx product candidate for patients with high-risk hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

The company's competitive edge lies in its proprietary DeltEx platform, which enables the development of gamma-delta T cell product candidates with unique properties. This platform employs allogeneic, autologous, induced pluripotent stem cell (iPSC), and genetically modified cell therapy approaches designed to effectively identify and eradicate tumor cells.

The DeltEx platform has been used to develop multiple product candidates, including INB-400, INB-200, and INB-100. These product candidates are in various stages of clinical trials. For instance, INB-400 is in a Phase 2 multi-center clinical trial, while INB-200 and INB-100 are in Phase 1 dose-escalation clinical trials.

IN8BIO's customers are primarily patients with solid and liquid tumors who are being treated with its product candidates. The company also collaborates with other biopharmaceutical companies and research institutions to develop its product candidates.

The DeltEx platform and the company's expertise in gamma-delta T cell biology set IN8BIO apart from its competitors. Its ability to develop product candidates that can be used in combination with other therapies further strengthens its position within the industry.

The company's product candidates include INB-400, INB-200, and INB-100. These are all gamma-delta T cell product candidates, with INB-400 and INB-200 being autologous DeltEx DRI product candidates for GBM, and INB-100 being an allogeneic DeltEx product candidate for patients with high-risk hematologic malignancies undergoing allogeneic HSCT.